Drugs / BM32
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01350635 | May → Jul 2011 | hypersensitivity reaction disease | Biomay AG | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02643641 | Jan → Oct 2016 | hypersensitivity reaction disease | Biomay AG | Completed | No outcome recorded |
| Phase 2 | NCT01538979 | Mar 2012 → Dec 2014 | seasonal allergic rhinitis | Biomay AG | Completed | No outcome recorded |
| Phase 2 | NCT01445002 | Oct 2011 → Mar 2012 | seasonal allergic rhinitis | Biomay AG | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM32 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01538979 ↗ |
| Modality | Vaccine | “BM32 is a hypoallergenic grass pollen allergy vaccine” NCT01350635 ↗ |
| Route | Other | “when applied by skin prick- and atopy patch testing to grass pollen allergic patients” NCT01350635 ↗ |